Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study on the Effect of Intracoronary Cryotherapy on Stabilization of Vulnerable Plaque at Risk of Rupture (ICEBERG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04857580
Recruitment Status : Not yet recruiting
First Posted : April 23, 2021
Last Update Posted : August 9, 2021
Sponsor:
Information provided by (Responsible Party):
Cryotherapeutics SA

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Atherosclerosis is a progressive inflammatory disease of the large and medium sized arteries, which is characterized by the formation of plaques in the vessel wall. The morphology and composition of the plaque play a major role in its stability during the development of the disease.

The CTS system allows to deliver coronary cryotherapy intended for stabilization of vulnerable plaque with non-significant stenosis. Vulnerable plaque at high risk of rupture will be assessed by NIRS-IVUS imaging modality in patients with Acute Coronary Syndrome (ACS).

The ICEBERG study is an early feasibility single arm study enrolling a maximum of 45 patients. After enrolment of the first 5 patients in the First-in-Man safety cohort, the trial will enroll and randomize 40 eligible lesions in the randomized cohort of which 20 will be treated with cryotherapy.


Condition or disease Intervention/treatment Phase
Acute Coronary Syndrome Device: CTS Device Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intracoronary Cryotherapy Effect for staBilization of vulnErable Plaque at Risk of Rupture as Assessed by imaGing
Estimated Study Start Date : August 2021
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tears

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CTS device Device: CTS Device
Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
No Intervention: Control


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cryotherapy procedure related complication [ Time Frame: 90 days ]
    Any cryotherapy procedure related complication defined as coronary artery dissection, acute vessel closure, ischemia, arrythmia, need for bailout stenting, or any Major Adverse Cardiac Events (MACE) adjudicated to the index lesion

  2. Optical Coherence Tomography (OCT)-assessed fibrous cap thickness [ Time Frame: 90 days ]
    Change in Optical Coherence Tomography (OCT)-assessed fibrous cap thickness from index lesion.


Secondary Outcome Measures :
  1. Cryotherapy related complication [ Time Frame: 9 months ]
    Any cryotherapy related complication defined as coronary artery dissection, acute vessel closure, ischemia, arrythmia, need for bailout stenting, or any MACE defined as cardiac death, myocardial infarction, revascularization, rehospitalization for unstable or progressive angina adjudicated to the index lesion.

  2. Device success [ Time Frame: Baseline ]
    Device success defined as ability to successfully track and treat the lesion.

  3. Cryotherapy/lesion procedure success [ Time Frame: Baseline ]
    Cryotherapy/lesion procedure success defined as TIMI 3 flow, percent diameter stenosis equivalent to or lower than pre-procedure.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women at least 18 years old.

  • Acute cardiac pain/angina consistent with acute coronary syndrome eligible for coronary angiography meeting one of the following criteria:

    1. Non ST-segment elevation myocardial infarction (NSTEMI) with rise/fall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring Percutaneous Coronary Intervention (PCI) within 72 hours from diagnosis
    2. Stabilized ST-segment elevation myocardial infarction (STEMI) with at least one value above the 99th percentile of the upper reference limit requiring PCI within < 12 hours from symptoms onset.
    3. Unstable angina with new or worsening angina symptoms over the last 2 weeks requiring PCI within 72 hours.
  • Patient must have one, two or three-vessel disease in native coronary arteries.
  • PCI of the culprit lesion on all patients.

  • At least one lesion meeting the criteria below:

    1. Located in a non-culprit vessel, or proximal to the culprit lesion if located in the culprit vessel with at least 10 mm distance from the culprit lesion.
    2. Lesion stenosis ≤ 70% of the reference vessel diameter by visual assessment on coronary angiogram.
    3. Plaque-level maxLCBI4mm ≥ 325 by NIRS (Near-Infrared Spectroscopy).
    4. Plaque burden ≥ 65% by IVUS (IntraVascular UltraSound).
    5. Not intended for revascularization based on angiographic criteria and negative physiology assessment (FFR>0.80 or iFR/RFR>0.89).
    6. Lesion-level balloon to artery ratio > 1.0.
    7. Lesion length ≤ 20 mm.
    8. Investigator considers that lesions are accessible.
    9. If more than two suitable lesions available, investigator will select two lesions for randomization.
  • Subject able to consent and has a signed and dated the informed consent form.

Exclusion Criteria:

  • Unstable patients (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP).
  • Patients with ongoing ST-segment elevation myocardial infarction.
  • Patients that had a procedural complication during the PCI procedure, such as coronary dissection, perforation or a complication that would necessitate immediate and/or unplanned surgical revascularization.
  • History of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure.
  • Known ejection fraction < 30%.
  • Known severe valvular heart disease.
  • Known severe renal insufficiency (eGFR <30 ml/min/1.72 m2).
  • Any life-threatening conditions or medical comorbidity resulting in life expectancy < 12 months.
  • Participation in any investigational study that has not yet reached its primary endpoint.
  • Women who are pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or women with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).

Angiographic exclusion criteria:

  • Visible distal embolization/no-reflow following culprit PCI.
  • Left main coronary artery disease (visual diameter stenosis > 50%).
  • Stent thrombosis/restenosis as a culprit lesion.
  • Index lesion involving a bifurcation.
  • Angiographic evidence of severe calcification and/or marked tortuosity of the index vessel and/or lesion.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Cryotherapeutics SA
ClinicalTrials.gov Identifier: NCT04857580    
Other Study ID Numbers: CT-CD-P01-1
First Posted: April 23, 2021    Key Record Dates
Last Update Posted: August 9, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Coronary Syndrome
Rupture
Myocardial Ischemia
Heart Diseases
 Cardiovascular Diseases
Vascular Diseases
Wounds and Injuries